XML 44 R27.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Schedule of aggregate stock option and award activity

Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, 2006 Directors Plan, Inducement Plan and Directors Market Plan is as follows:

 

 

 

 

 

 

Outstanding Stock Options

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average

 

 

Aggregate

 

 

 

Shares

 

 

 

 

 

Weighted Average

 

 

Remaining

 

 

Intrinsic

 

 

 

Available

 

 

Number of

 

 

Exercise Price

 

 

Contractual Life

 

 

Value

 

 

 

For Grant

 

 

Shares

 

 

Per Share

 

 

(In years)

 

 

(In thousands)

 

Balance at December 31, 2021

 

 

18,763,393

 

 

 

49,952,409

 

 

$

2.06

 

 

 

 

 

 

 

Additional shares authorized

 

 

16,755,000

 

 

 

 

 

$

 

 

 

 

 

 

 

Stock options granted

 

 

(19,747,760

)

 

 

19,747,760

 

 

$

1.37

 

 

 

 

 

 

 

Awards granted

 

 

(15,962

)

 

 

 

 

$

 

 

 

 

 

 

 

Stock options exercised

 

 

 

 

 

(1,181,711

)

 

$

1.52

 

 

 

 

 

 

 

Stock options cancelled/forfeited/expired

 

 

2,616,058

 

 

 

(2,616,058

)

 

$

1.70

 

 

 

 

 

 

 

Balance at December 31, 2022

 

 

18,370,729

 

 

 

65,902,400

 

(1)

$

1.87

 

 

 

6.56

 

 

$

50,205

 

Stock options exercisable at
  December 31, 2022

 

 

 

 

 

36,085,389

 

 

$

2.17

 

 

 

5.09

 

 

$

22,878

 

Stock options fully vested and expected
    to vest at December 31, 2022

 

 

 

 

 

64,539,649

 

 

$

1.88

 

 

 

6.52

 

 

$

48,951

 

 

(1)
Includes 8,791,750 performance-based stock options granted that have not achieved certain strategic milestones.
Summary of allocation of stock-based compensation expense related to share-based payment awards

We recognize stock‑based compensation expense for service-based stock options on a straight‑line basis over the requisite service period, which is generally the vesting period. We have not recognized any stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the years ended December 31, 2022, 2021 and 2020, as the achievement of the specified strategic milestones was not considered probable during that time. The following table summarizes the stock‑based compensation expense related to service-based stock options and employee stock purchases for the years ended December 31, 2022, 2021 and 2020 which was allocated as follows:

 

 

 

Year Ended December 31,

 

(In thousands)

 

2022

 

 

2021

 

 

2020

 

Research and development

 

$

3,720

 

 

$

3,597

 

 

$

2,337

 

General and administrative

 

 

4,281

 

 

 

4,483

 

 

 

4,558

 

Stock-based compensation expense
   included in operating expenses

 

$

8,001

 

 

$

8,080

 

 

$

6,895

 

 

Schedule of assumptions used to estimate the fair value of stock options granted

The fair value of stock options granted in 2022, 2021, and 2020 has been estimated at the date of grant using the Black Scholes option‑pricing model with the following assumptions:

 

 

 

Year Ended December 31,

 

 

2022

 

2021

 

2020

Dividend yield

 

0%

 

0%

 

0%

Expected volatility range

 

0.772 to 0.817

 

0.775 to 0.783

 

0.781 to 0.793

Risk-free interest rate range

 

1.69% to 4.57%

 

0.51% to 1.30%

 

0.31% to 1.62%

Expected term range

 

5.5 yrs

 

5.5 yrs

 

5.25 yrs

 

Schedule of assumptions used to estimate the fair value of employee stock purchases under the purchase plan

The fair value of employee stock purchases in 2022, 2021, and 2020 has been estimated using the Black Scholes option‑pricing model with the following assumptions:

 

 

 

Year Ended December 31,

 

 

2022

 

2021

 

2020

Dividend yield

 

0%

 

0%

 

0%

Expected volatility range

 

0.614 to 0.865

 

0.507 to 0.707

 

0.478 to 0.818

Risk-free interest rate range

 

0.40% to 2.79%

 

0.09% to 0.16%

 

0.16% to 1.57%

Expected term range

 

6 - 12 mos

 

6 - 12 mos

 

6 - 12 mos

 

Schedule of common stock reserved for future issuance

Common stock reserved for future issuance as of December 31, 2022 is as follows:

 

Outstanding stock options

 

 

65,902,400

 

Stock options and awards available for grant

 

 

18,370,729

 

Employee stock purchase plan

 

 

1,131,764

 

Warrants outstanding

 

 

106,254,842

 

Total

 

 

191,659,735